We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Biomedicine

Search Results

Showing 81-100 of 674 results

  1. Abuse and Dependence Liability of GABAA-Receptor Modulators

    Ligands that act at γ-aminobutyric type A (GABAA) receptors, in particular the benzodiazepines and related drugs, have broad clinical use but also...
    James K. Rowlett, Angela N. Duke, Donna M. Platt in The GABA Receptors
    Chapter 2007

  2. Chiral selective effects of doxazosin enantiomers on blood pressure and urinary bladder pressure in anesthetized rats

    Aim:

    To study chiral selective effects of doxazosin enantiomers on blood pressure and urinary bladder pressure in anesthetized rats.

    Methods: ...
    Shi-** Ma, Lei-ming Ren, ... Li-hua Duan in Acta Pharmacologica Sinica
    Article 01 November 2006

  3. 5HT3 antagonism abolishes the emotion potentiated startle effect in humans

    Rationale

    The serotonergic system has been implicated in emotional processing in animals and humans. Although the contribution of different receptor...

    Catherine J. Harmer, Catriona B. Reid, ... Philip J. Cowen in Psychopharmacology
    Article 30 March 2006

  4. Poster abstracts

    J. Ferrie, M. Shipley, ... H. Richards in Sleep and Biological Rhythms
    Article 01 August 2007

  5. Acquisition and extinction of a conditioned passive avoidance reflex in mice with genetic knockout of monoamine oxidase A

    We report here the results obtained from comparative analysis of learning and the dynamics of extinction of a conditioned passive avoidance response...

    N. I. Dubrovina, N. K. Popova, ... I. Seif in Neuroscience and Behavioral Physiology
    Article 01 May 2006

  6. Animal Models of Anxiety

    Anxiety is a complex neurobehavioral disorder that often includes co-morbid features, e.g., obsessive-compulsive behavior. Animal models can be...
    Robert Gerlai, Robert Blanchard, Caroline Blanchard in Transgenic and Knockout Models of Neuropsychiatric Disorders
    Chapter 2006

  7. Patent issues in drug development: Perspectives of a pharmaceutical scientist-attorney

    The major purpose of this article is to emphasize the need for pharmaceutical scientists to have a better understanding of patent fundamentals. This...

    Srikumaran Melethil in The AAPS Journal
    Article 01 September 2005

  8. Treatment of cerebellar ataxia with 5-HT1A agonist

    Effective, pharmacologic approaches to the treatment of cerebellar ataxia are lacking or inadequate. We recently reported preliminary evidence that...

    Asako Takei, Takeshi Hamada, ... Hidenao Sasaki in The Cerebellum
    Article 01 September 2005

  9. Transgenic Mouse Models and Human Psychiatric Disease

    Genetic susceptibility to common psychiatric disease arises from the complex interactions between a multitude of genes and an unknown number of...
    Jonathan Flint in Transgenic and Knockout Models of Neuropsychiatric Disorders
    Chapter 2006

  10. NMDA Receptors Mediate Consolidation of Contextual Memory in the Hippocampus after Context Preexposure

    Male Wistar rats received bilateral infusions of vehicle (VEH) or aminophosphonopentanoic acid (AP5), an N -metil-D-aspartate (NMDA) receptor...

    Rafael Roesler, Gustavo K. Reolon, ... João Quevedo in Neurochemical Research
    Article 01 November 2005

  11. Animal Models of Psychosis

    Although the thinking and affective and social disturbances of psychosis and schizophrenia may not be easily modeled, if at all, in infrahuman...
    Stephen I. Deutsch, Katrice Long, ... John Mastropaolo in Transgenic and Knockout Models of Neuropsychiatric Disorders
    Chapter 2006

  12. A Model of Anxious Depression: Persistence of Behavioral Pathology

    Chronic psychoemotional stress induced by negative experience of social defeats in intermale confrontations over a period of 30 days was found to...

    D. F. Avgustinovich, I. L. Kovalenko, N. N. Kudryavtseva in Neuroscience and Behavioral Physiology
    Article 01 November 2005

  13. Central Nervous System (CNS) Safety Pharmacology Studies

    Roger D. Porsolt, Vincent Castagné, ... Charles P. France in Drug Discovery and Evaluation
    Reference work entry 2006

  14. Advances in the treatment of anxiety: Targeting glutamate

    Our current psychopharmacological treatments for anxiety disorders evince a number of shortcomings, including troublesome side effects and lack of...

    Asher B. Simon, Jack M. Gorman in NeuroRX
    Article 01 January 2006

  15. Metabolism and Receptor Binding of Serotonin in Brain Structures During Performance of a Conditioned Passive Avoidance Response

    The levels of serotonin and its metabolite 5-hydroxyindoleacetic acid, monoamine oxidase activity, and the specific binding of the radioligand [ 3 H]ser...

    G. F. Molodtsova in Neuroscience and Behavioral Physiology
    Article 01 September 2005

  16. The Serotonin 1A A Receptor: A Representative Member of the Serotonin Receptor Family

    1. Serotonin is an intrinsically fluorescent biogenic amine that acts as a neurotransmitter and is found in a wide variety of sites in the central...

    Thomas J. Pucadyil, Shanti Kalipatnapu, Amitabha Chattopadhyay in Cellular and Molecular Neurobiology
    Article 01 June 2005

  17. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development

    In this review, the value of functional imaging [positron emission tomography (PET)/single-photon emission computed tomography (SPECT)] in drug...

    David J. Brooks in NeuroRX
    Article 01 April 2005

  18. The wide spectrum of spinocerebellar ataxias (SCAs)

    Spinocerebellar ataxias (SCAs) are a clinically heterogeneous group of disorders. Current molecular classification corresponds to the order of gene...

    Mario-Ubaldo Manto in The Cerebellum
    Article 01 March 2005

  19. Role of Nitric Oxide on Motor Behavior

    The present review paper describes results indicating the influence of nitric oxide (NO) on motor control. Our last studies showed that systemic...

    E. A. Del Bel, F. S. Guimarães, ... D. de Paula-Souza1 in Cellular and Molecular Neurobiology
    Article 01 April 2005

  20. Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice

    Aim:

    To investigate the effects of orexin A on release of histamine, norepinephrine, and serotonin in the frontal cortex of mice.

    Methods: ...
    Zong-yuan Hong, Zhi-li Huang, ... Naomi Eguchi in Acta Pharmacologica Sinica
    Article 01 February 2005
Did you find what you were looking for? Share feedback.